A study by Barra et al. suggests that long-acting glucagon-like peptide-1 (GLP-1) analogues, which are used as a treatment for obesity, may help to restore natural killer (NK) cell function in people with obesity (PWO). In a study of 20 PWO, GLP-1 therapy was found to improve NK cell function, as measured by cytotoxicity and interferon-γ/granzyme B production, and increase a CD98-mTOR-glycolysis metabolic axis critical for NK cell cytokine production. These findings suggest that GLP-1 therapy could potentially contribute to the overall benefits of this class of medication beyond just weight loss.
Related Posts
Anxiety: More Than Just a Feeling
Fear and anxiety aren’t just in your mind, as psychiatrist and neuroscientist Arash Javanbakht explains. While the brain processes these emotions, they manifest throughout the body. The amygdala, a key brain region, triggers physical responses rapidly when danger is perceived. The hippocampus contextualizes fear, differentiating between real threats and safe situations. The prefrontal cortex […]
Lactic Acid Bacteria: A Tiny Powerhouse with Big Potential
Lactic acid bacteria (LAB) are more than just the bacteria that give yogurt its tangy taste. These versatile microorganisms have a wide range of potential applications in food, medicine, and beyond. What are LAB? LAB are a group of bacteria that ferment carbohydrates, producing lactic acid as a byproduct. This fermentation process gives many fermented […]
Professor Li Tang’s groundbreaking research enhances CAR-T cell therapy by introducing a new dimension to target solid tumors. Co-founding Leman Biotech with Yugang Guo, Tang’s bioengineered CAR-T cells excrete the IL-10 molecule, traditionally seen as an immune suppressant. Rather than inhibiting the immune response, this innovation reinforces metabolic capabilities, addressing the challenge of CAR-T cells […]